[PRESS RELEASE] – NEW YORK, Aug. 13, 2025 – Tilray Medical, a division of Tilray Brands Inc. and a global leader in medical cannabis, empowering the therapeutic alliance between patients and health care practitioners to make informed individualized health decisions, announced that its wholly-owned subsidiary, FL Group S.R.L., has entered into a strategic partnership with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. (“Molteni”), an Italian pharmaceutical firm specializing in pain therapies and substance dependence.
The partnership is designed to broaden the availability of Tilray Medical cannabis extracts for patients across Italy. Molteni will collaborate with FL Group by providing targeted education on medical cannabis therapies through Molteni’s comprehensive network of pharmaceutical, scientific and medical professionals throughout Italy.
“This partnership reflects our commitment to advancing patient care through strategic collaboration,” said Rajnish Ohri, managing director of international at Tilray Brands. “By combining FL Group’s regulatory and distribution capabilities with Molteni’s scientific leadership, we are not only expanding access to high-quality, EU-GMP certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni’s extensive network of health care professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions.”
Tilray Medical continues to lead the European medical cannabis market with operations in Germany, Italy, Portugal, Poland and the United Kingdom.
